Technology in Cancer Research & Treatment (Sep 2023)

miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance

  • Ali Tavakoli Pirzaman MD,
  • Pouyan Ebrahimi MD,
  • Amir Hossein Hasanpour MD,
  • Mahdi Shakeri MD,
  • Bahareh Babajani MS,
  • Zahra Pourali Ganji MS,
  • Hedye Babaei MD,
  • Amirhossein Rahmati MS,
  • Rezvan Hosseinzadeh MD,
  • Shahrbanoo Doostmohamadian MS,
  • Sohrab Kazemi PhD

DOI
https://doi.org/10.1177/15330338231202391
Journal volume & issue
Vol. 22

Abstract

Read online

Multiple myeloma (MM) produces clonal plasma cells and aberrant monoclonal antibody accumulation in patients’ bone marrow (BM). Around 1% of all cancers and 13% of hematological malignancies are caused by MM, making it one of the most common types of cancer. Diagnostic and therapeutic methods for managing MM are currently undergoing extensive research. MicroRNAs (miRNAs) are short noncoding RNAs that reduce or inhibit the translation of their target mRNA after transcription. Because miRNAs play an influential role in how myeloma develops, resources, and becomes resistant to drugs, miRNA signatures may be used to diagnose, do prognosis, and treat the myeloma response. Consequently, researchers have investigated the levels of miRNA in plasma cells from MM patients and developed tools to test whether they directly impacted tumor growth. This review discusses the latest discoveries in miRNA science and their role in the development of MM. We also emphasize the potential applications of miRNAs to diagnose, prognosticate, and treat MM in the future.